Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Inventory (2016 - 2023)

Historic Inventory for Perspective Therapeutics (CATX) over the last 13 years, with Q3 2023 value amounting to $1.0 million.

  • Perspective Therapeutics' Inventory fell 3477.14% to $1.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $1.0 million, marking a year-over-year decrease of 3477.14%. This contributed to the annual value of $1.4 million for FY2022, which is N/A changed from last year.
  • Latest data reveals that Perspective Therapeutics reported Inventory of $1.0 million as of Q3 2023, which was down 3477.14% from $1.1 million recorded in Q2 2023.
  • Perspective Therapeutics' 5-year Inventory high stood at $1.6 million for Q3 2022, and its period low was $501000.0 during Q3 2019.
  • Its 5-year average for Inventory is $921842.1, with a median of $980000.0 in 2021.
  • In the last 5 years, Perspective Therapeutics' Inventory soared by 6536.66% in 2021 and then crashed by 3477.14% in 2023.
  • Over the past 5 years, Perspective Therapeutics' Inventory (Quarter) stood at $545000.0 in 2019, then grew by 22.02% to $665000.0 in 2020, then soared by 60.6% to $1.1 million in 2021, then surged by 31.93% to $1.4 million in 2022, then decreased by 28.11% to $1.0 million in 2023.
  • Its last three reported values are $1.0 million in Q3 2023, $1.1 million for Q2 2023, and $1.4 million during Q1 2023.